Supreme Court Keeps Mifepristone Access
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Supreme Court (via Justice Samuel Alito) issued a temporary order on Monday, preserving pharmacy and mail access to mifepristone and halting a 5th Circuit ruling that would have suspended telehealth and mail distribution at least through Thursday.
- Louisiana sued to roll back FDA prescribing rules for mifepristone, arguing the policy undermines the state’s abortion ban and raises safety concerns about the drug.
- FDA originally approved mifepristone in 2000 and has since eased restrictions on prescribing, dispensing, and safety reporting, maintaining that the drug is safe and effective.
- U.S. data from 2023 show medication abortions accounted for nearly two‑thirds of all abortions in the country.
Why it matters: Women seeking abortions keep access to mifepristone until at least Thursday, preserving an option for the nearly two‑thirds of U.S. abortions that rely on medication, while the Supreme Court’s pending ruling will decide if Louisiana’s challenge can curb that access.
Ask SkimNews
